Clinical Study

Plasma Granzyme B in ST Elevation Myocardial Infarction versus Non-ST Elevation Acute Coronary Syndrome: Comparisons with IL-18 and Fractalkine

Table 2

Demographic data and biochemical parameters in STEMI and NSTEMI/UA groups.

GroupsNSTEMI/UASTEMI
Factor/ 1422

Age (years)50.5 ± 0.7550.32 ± 0.63NS
Sex (M/F)8/618/4NS
BMI (kg/m2)29 ± 0.6827.95 ± 0.31NS
Current smoker, (%)5 (36% )9 (41%)NS
Prior ACS, (%)11 (78%)5 (23%)
SBP (mmHg)130.71 ± 6.06125 ± 5.29NS
DBP (mmHg)80.7 ± 5.676.8 ± 2.7NS
Hypertension, (%)8 (57%)12 (55%)NS
HR (bpm)83.3 ± 2.185.3 ± 3.2NS
LVEF (%)51.3 ± 3.147.6 ± 2.2NS
Peak CK (IU/L)407.8 ± 121.21874.4 ± 231<0.001
Peak CK-MB (IU/L)88.3 ± 22.6235.6 ± 24.3<0.001
Treatment (BB/CCB/ACEI/diuretics/nitrates/statins)13/0/8/1/4/1311/2/13/4/2/19
TAG (mmol/L)1.23 ± 0.041.27 ± 0.02NS
TC (mmol/L)5.04 ± 0.135.34 ± 0.09NS
HDL-C (mmol/L)0.9 ± 0.040.92 ± 0.03NS
LDL-C (mmol/L)3.52 ± 0.123.73 ± 0.05NS
LDL-C/HDL-C4 ± 0.24.15 ± 0.2NS
TC/HDL-C5.7 ± 0.35.9 ± 0.2NS
Hypercholesterolemia, (%)5 (36%)15 (68%)NS
hsCRP (mg/L)6.4 ± 0.511.3 ± 0.6<0.001
GZB (pg/L)158.1 ± 9.7254.6 ± 21.8<0.01
IL-18 (pg/mL)99.8 ± 3.692 ± 3.6NS
FKN (pg/mL)598.2 ± 32662.1 ± 30.3NS

Results are mean ± SEM.
ACEI: angiotensin converting enzyme inhibitor; BB: beta blocker; CCB: calcium channel blocker; CK: creatine kinase; CK-MB: creatine kinase MB fraction; DBP: diastolic blood pressure; HDL-C: high density lipoprotein cholesterol; HR: heart rate; LDL-C: low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; NS: not significant; SBP: systolic blood pressure; TAG: triacylglycerol; TC: total cholesterol.